CANQURA is now developing this novel type of anti-cancer treatment, based on nanoparticles of natural origin. The mode of action reprograms cancer cells to stop dividing and multiplying, then differentiate and proceed to normal cell death in more than 19 types of cancer. Additionally in combination with other anti-cancer therapies, these effects are obtained without negative effects on healthy cells. The resulting product is referred to as C-100. Following an Agreement and the recent acquisition of our vaccine adjuvant technology, C-100 is produced by Croda International PLC. Other potential uses for C-100 planned for development are as a drug carrier “Delphateq” where initial tests also proved very encouraging.